Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rett syndrome
Biotech
Anavex stock sinks 30% as lead asset fails in Rett syndrome
Anavex’s lead asset has failed to significantly improve disease characteristics in a pediatric Rett syndrome trial.
Gabrielle Masson
Jan 2, 2024 12:08pm
Astellas continues gene therapy push with $50M stake in Taysha
Oct 24, 2022 7:30pm
Alcyone unveils with $23M for 12 AAV gene therapies for CNS
Jun 9, 2021 10:40am